To ascertain the therapeutic potential of PPAR-γ ligands we examined their ability to suppress Akt and FAK in bona fide diseased primary lung fibroblasts obtained from patients with IPF. This evidence concerns the gene PPARG and idiopathic pulmonary fibrosis.